Dr. Nicholas J. Sanfilippo, MD

Dr. Sanfilippo practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Sanfilippo's NPI, 1902807779, was assigned on August 3, 2005. Dr. Sanfilippo graduated from UVA School of Medicine in 1995. Dr. Sanfilippo holds New York license 217645.

Dr. Sanfilippo's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Sanfilippo's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. Dr. Sanfilippo is also affiliated with Tisch Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Sanfilippo to 2 more clinical labs and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sanfilippo practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Sanfilippo's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Sanfilippo is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Sanfilippo's licenses on file in 6 states: New York, Florida, New Jersey, Virginia, Connecticut and Pennsylvania.

Dmand AI lists anal cancer radiation, bone cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Sanfilippo treats.

CMS data shows 2,459 Medicare services from Dr. Sanfilippo across 19 procedure codes in 2024, for 322 Medicare patients. Medicare paid $221,901 for them.

CMS counts 322 Medicare patients who saw Dr. Sanfilippo in 2024. The largest group is 75 to 84, with 145 patients. 75% of them have cancer, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sanfilippo's median patient age at 77, with 44% women.

In 2016, Dr. Sanfilippo wrote 30 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $834 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sanfilippo for performance year 2024, reported through an alternative payment model (APM). Dr. Sanfilippo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sanfilippo as offering telehealth.

Dmand AI links 33 papers to Dr. Sanfilippo, published from 2006 to 2024. 2014 was the busiest year, with 3. The most frequent topics are Carcinoma, Squamous Cell, Prostatic Neoplasms and Radiotherapy Dosage. Dr. Sanfilippo has published most often in Int J Radiat Oncol Biol Phys. Dr. Sanfilippo's most frequent co-authors are Benjamin Cooper, MD, Mark Delacure, MD and Kevin Du, MD.

Dmand AI links Dr. Sanfilippo to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 3 general payments to Dr. Sanfilippo from 3 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 65% of the total. Viewray Technologies Inc paid the most, $149.

Dmand AI lists 1 award for Dr. Sanfilippo, most recently CMS Stage 1 EHR in 2013.

Dr. Sanfilippo graduated from UVA School of Medicine in 1995.

Dr. Sanfilippo is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.